289 related articles for article (PubMed ID: 33106857)
1. Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.
Casar-Borota O; Boldt HB; Engström BE; Andersen MS; Baussart B; Bengtsson D; Berinder K; Ekman B; Feldt-Rasmussen U; Höybye C; Jørgensen JOL; Kolnes AJ; Korbonits M; Rasmussen ÅK; Lindsay JR; Loughrey PB; Maiter D; Manojlovic-Gacic E; Pahnke J; Poliani PL; Popovic V; Ragnarsson O; Schalin-Jäntti C; Scheie D; Tóth M; Villa C; Wirenfeldt M; Kunicki J; Burman P
J Clin Endocrinol Metab; 2021 Mar; 106(4):1183-1194. PubMed ID: 33106857
[TBL] [Abstract][Full Text] [Related]
2. USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors.
Uzilov AV; Taik P; Cheesman KC; Javanmard P; Ying K; Roehnelt A; Wang H; Fink MY; Lau CY; Moe AS; Villar J; Bederson JB; Stewart AF; Donovan MJ; Mahajan M; Sebra R; Post KD; Chen R; Geer EB
J Clin Endocrinol Metab; 2021 Mar; 106(3):826-842. PubMed ID: 33221858
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.
Rak B; Maksymowicz M; Pękul M; Zieliński G
Front Endocrinol (Lausanne); 2021; 12():672178. PubMed ID: 34135861
[TBL] [Abstract][Full Text] [Related]
4. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study.
Ilie MD; Villa C; Cuny T; Cortet C; Assie G; Baussart B; Cancel M; Chanson P; Decoudier B; Deluche E; Di Stefano AL; Drui D; Gaillard S; Goichot B; Huillard O; Joncour A; Larrieu-Ciron D; Libe R; Nars G; Vasiljevic A; Raverot G
Eur J Endocrinol; 2022 Nov; 187(5):685-696. PubMed ID: 36111659
[TBL] [Abstract][Full Text] [Related]
5. ACTH-secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and review of the literature.
Sumislawski P; Rotermund R; Klose S; Lautenbach A; Wefers AK; Soltwedel C; Mohammadi B; Jacobsen F; Mawrin C; Flitsch J; Saeger W
Endocrine; 2022 Apr; 76(1):228-236. PubMed ID: 35171439
[No Abstract] [Full Text] [Related]
6. Identification of a novel
Uzilov AV; Cheesman KC; Fink MY; Newman LC; Pandya C; Lalazar Y; Hefti M; Fowkes M; Deikus G; Lau CY; Moe AS; Kinoshita Y; Kasai Y; Zweig M; Gupta A; Starcevic D; Mahajan M; Schadt EE; Post KD; Donovan MJ; Sebra R; Chen R; Geer EB
Cold Spring Harb Mol Case Stud; 2017 May; 3(3):a001602. PubMed ID: 28487882
[TBL] [Abstract][Full Text] [Related]
7. Serotonin, ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis of Neuroendocrine Tumors of the Sellar Region.
Casar-Borota O; Botling J; Granberg D; Stigare J; Wikström J; Boldt HB; Kristensen BW; Pontén F; Trouillas J
Am J Surg Pathol; 2017 Sep; 41(9):1238-1246. PubMed ID: 28719461
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
9. Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.
Lasolle H; Elsensohn MH; Wierinckx A; Alix E; Bonnefille C; Vasiljevic A; Cortet C; Decoudier B; Sturm N; Gaillard S; Ferrière A; Roy P; Jouanneau E; Bertolino P; Bardel C; Sanlaville D; Raverot G
Acta Neuropathol Commun; 2020 Nov; 8(1):190. PubMed ID: 33168091
[TBL] [Abstract][Full Text] [Related]
10. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors.
de Wilde RF; Heaphy CM; Maitra A; Meeker AK; Edil BH; Wolfgang CL; Ellison TA; Schulick RD; Molenaar IQ; Valk GD; Vriens MR; Borel Rinkes IH; Offerhaus GJ; Hruban RH; Matsukuma KE
Mod Pathol; 2012 Jul; 25(7):1033-9. PubMed ID: 22575867
[TBL] [Abstract][Full Text] [Related]
11. The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease.
Perez-Rivas LG; Theodoropoulou M; Ferraù F; Nusser C; Kawaguchi K; Stratakis CA; Faucz FR; Wildemberg LE; Assié G; Beschorner R; Dimopoulou C; Buchfelder M; Popovic V; Berr CM; Tóth M; Ardisasmita AI; Honegger J; Bertherat J; Gadelha MR; Beuschlein F; Stalla G; Komada M; Korbonits M; Reincke M
J Clin Endocrinol Metab; 2015 Jul; 100(7):E997-1004. PubMed ID: 25942478
[TBL] [Abstract][Full Text] [Related]
12. Pituitary corticotroph tumour with adrenocortical cells: A distinct clinicopathologic entity with unique morphology and methylation profile.
Hickman RA; Gionco JT; Faust PL; Miller ML; Bruce J; Page-Wilson G; Rosenblum MK; Asa SL
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12754. PubMed ID: 34296770
[TBL] [Abstract][Full Text] [Related]
13. β-arrestin expression in corticotroph tumor cells is modulated by glucocorticoids.
Gatto F; Feelders RA; van der Pas R; van Koetsveld P; Bruzzone E; Arvigo M; Dogan F; Lamberts S; Ferone D; Hofland L
J Endocrinol; 2020 Apr; 245(1):101-113. PubMed ID: 32027601
[TBL] [Abstract][Full Text] [Related]
14. Human kallikrein 10 expression in surgically removed human pituitary corticotroph adenomas: an immunohistochemical study.
Di Meo A; Rotondo F; Kovacs K; Cusimano MD; Syro LV; Di Ieva A; Diamandis EP; Yousef GM
Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):433-7. PubMed ID: 25517869
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of silent corticotroph pituitary neuroendocrine tumors (PitNETs) from non-functioning PitNETs using kinetic analysis of dynamic MRI.
Amano T; Masumoto T; Watanabe D; Hoshiai S; Mori K; Sakamoto N; Kino H; Akutsu H; Nakajima T
Jpn J Radiol; 2023 Sep; 41(9):938-946. PubMed ID: 37027094
[TBL] [Abstract][Full Text] [Related]
16. Aggressive corticotroph tumors and carcinomas.
Lasolle H; Vasiljevic A; Jouanneau E; Ilie MD; Raverot G
J Neuroendocrinol; 2022 Aug; 34(8):e13169. PubMed ID: 35979732
[TBL] [Abstract][Full Text] [Related]
17. The Genomic Landscape of Corticotroph Tumors: From Silent Adenomas to ACTH-Secreting Carcinomas.
Andonegui-Elguera S; Silva-Román G; Peña-Martínez E; Taniguchi-Ponciano K; Vela-Patiño S; Remba-Shapiro I; Gómez-Apo E; Espinosa-de-Los-Monteros AL; Portocarrero-Ortiz LA; Guinto G; Moreno-Jimenez S; Chavez-Macias L; Saucedo R; Basurto-Acevedo L; Lopez-Felix B; Gonzalez-Torres C; Gaytan-Cervantes J; Ayala-Sumuano JT; Burak-Leipuner A; Marrero-Rodríguez D; Mercado M
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563252
[TBL] [Abstract][Full Text] [Related]
18. Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
Alzoubi H; Minasi S; Gianno F; Antonelli M; Belardinilli F; Giangaspero F; Jaffrain-Rea ML; Buttarelli FR
Endocr Pathol; 2022 Dec; 33(4):494-505. PubMed ID: 34993885
[TBL] [Abstract][Full Text] [Related]
19. Why don't corticotroph tumors always produce Cushing's disease?
García-Martínez A; Cano DA; Flores-Martínez A; Gil J; Puig-Domingo M; Webb SM; Soto-Moreno A; Picó A
Eur J Endocrinol; 2019 Sep; 181(3):351-361. PubMed ID: 31319379
[TBL] [Abstract][Full Text] [Related]
20. Pituitary Adenoma in Pediatric and Adolescent Populations.
Chen J; Schmidt RE; Dahiya S
J Neuropathol Exp Neurol; 2019 Jul; 78(7):626-632. PubMed ID: 31115468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
